Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2017

At a glance

  • Drugs Talactoferrin alfa (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 05 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top